Logo

MorphoSys Terminates Merger Talks

Oct 23, 2002

NEW YORK, Oct. 23-The German synthetic antibody firm MorphoSys said today that it had terminated merger talks with British Biotech, a publicly owned drug development company.

 

MorphoSys said that it did not expect to realize any equity-based transactions or partnerships this year, and reduced its year-end cash position guidance to roughly € 15 million.  The company held cash and cash equivalents of € 568,987 as of June 30, 2002.

Breaking News
The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.